Smegglutide Breakthrough in Fatty Liver Treatment: Mechanism and Clinical Overview of Liver Fibrosis Reversal in 57% of Patients
Share
I. MASH: The Silent "Chronic Fire" of the Liver, Urgently Needing Effective Treatment
Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) is a progressive form of fatty liver disease, and its pathological evolution is figuratively described as a "triple crisis of the liver."
● Fat accumulation : Excessive fat deposition in the liver (fatty degeneration)
● Inflammatory Outbreak : Immune cell infiltration triggers persistent inflammation
● Fibrotic scars : Repeated inflammation and damage lead to collagen deposition, and the liver gradually hardens.
Without intervention, MASH can develop into cirrhosis or hepatocellular carcinoma (HCC). Even more concerning is that MASH is often asymptomatic in its early stages, and by the time of diagnosis, it has usually progressed to the middle or late stages of fibrosis. The global prevalence has surged from 25.3% in 1990 to 38.2% in 2019, while existing treatment options are extremely limited.
Warning : Recent research has found that even among individuals with "metabolic healthy obesity" (MHO), those with MASLD (fatty liver disease) have a significantly increased 10-year cardiovascular risk and a three-fold increased risk of diabetes. Scholars are therefore calling for fatty liver to be included in the exclusion criteria for MHO —the presence of fatty liver disqualifies them from being considered "metabolic healthy."
II. The "Triple Benefits" of Smegglutinin: Liver Protection Beyond Weight Loss
Smegglutinin, a GLP-1 receptor agonist, was initially known for its weight loss and blood sugar-lowering effects. However, two groundbreaking studies published in the New England Journal of Medicine (NEJM) and Nature Medicine in 2025 revealed its deeper therapeutic mechanism against MASH:
1. Clinical evidence: The fibrosis reversal rate reaches 57%, demonstrating significant therapeutic effect.
● Phase 3 clinical trial (n=1197): In the semaglutide group, 62.9% of patients achieved "remission of steatohepatitis + no worsening of fibrosis", compared to only 34.3% in the placebo group ( difference 28.7%, P<0.001 ); 36.8% of patients achieved "improvement of fibrosis + no worsening of hepatitis", compared to only 22.4% in the placebo group.
● Proteomics follow-up study (n=249): After 72 weeks of treatment with 0.4 mg semaglutide, fibrosis was reversed in 57% of patients (16% in the placebo group) and inflammation was relieved in 82% of patients (32% in the placebo group).
2. Mechanism of action: Dual pathway synergy, directly targeting the core of fibrosis.
Smegglutinin's liver protection is achieved through a "dual engine":
● Weight loss-dependent pathway (contribution rate 69.3%) → Improves steatosis and hepatocellular damage
● Direct anti-fibrotic pathway independent of weight loss (contribution rate 25.1%) → Targeted regulation of collagen synthesis and inflammation
Animal experimental evidence : In the "lean fibrotic mouse model" (without obese background), smegglutinin still significantly reduced collagen deposition ( P<0.0001 ), demonstrating that its anti-fibrotic effect is independent of weight loss.
3. Breakthrough in Proteomics: 72 Proteins Reveal New Pathways for Non-invasive Monitoring
Using SomaScan technology to analyze nearly 5,000 serum proteins, researchers identified 72 key proteins (such as PTGR1, GUSB, and ACY1) that significantly normalized after semaglutide treatment. These proteins can be used to construct a non-invasive diagnostic model (SomaSignal test) to accurately predict four major pathological states of the liver.
● Steatosis (S value), inflammation (I value), hepatocellular damage (B value), fibrosis (F value)
Clinical significance : In the future, it may replace liver biopsy to achieve dynamic monitoring of treatment response.
III. A Holistic View of Clinical Value: From Liver to Multi-Organ Protection
The benefits of smegglutinin extend beyond the liver, forming a protective chain of "metabolism-cardiovascular-kidney":
● Cardiovascular : The SELECT trial confirmed that semaglutide reduces the risk of myocardial infarction/stroke/cardiovascular death by 20% in obese patients with cardiovascular disease (regardless of the degree of weight loss).
● Kidneys : The FLOW trial showed that smegglutinin reduced the risk of kidney failure by 24% in patients with diabetic nephropathy.
● Metabolic linkage : Improves insulin sensitivity, reduces triglycerides, and synergistically reverses the pathogenesis of MASLD.
Safety: Extremely low risk of liver damage, manageable gastrointestinal reactions.
● Metabolic pathway : Smegglutinin is mainly excreted via the kidneys (not metabolized by the liver), with a very low risk of direct liver damage.
● Main side effects : Gastrointestinal reactions such as nausea and vomiting (occurrence rate of approximately 79.6%), mostly transient and mild to moderate.
Precautions : Patients with a history of gallbladder disease should be alert to the risk of cholestasis, and those with liver dysfunction should have their enzyme levels monitored more closely .
IV. Future Outlook: Breakthroughs in Dual-Target Drugs and Combination Therapies
Smegglutide monotherapy is not the end goal; a new generation of multi-target agonists and combination strategies are emerging.
1. Dual/triple target agonists :
a. Survodutide (GLP-1R/GCGR dual antibody): MASH response rate 62% vs placebo 14%
b. HDM1005 (Huadong Medicine GLP-1R/GIPR bispecific antibody): Patented in both China and the US, with plans to treat multiple indications including fatty liver and heart failure.
2. Combination therapy :
a. CagriSema (semaglutide + canagliflozin): 20.4% weight loss in 68 weeks, improved efficacy compared to monotherapy.
Conclusion: Redefining the "rules of the game" in fatty liver treatment.
Smegglutide, through a dual mechanism of "weight loss + direct anti-fibrosis," has achieved pathological reversal of MASH for the first time. Its value lies not only in the 57% improvement rate in fibrosis, but also in:
● Provides non-invasive monitoring tools (proteomics models)
● Comprehensive protection for heart and kidney metabolism
● Promoting the development of combination therapies and multi-target drugs
With the progress of the Phase III ESSENCE trial, semaglutide is expected to become the first approved MASH targeted drug, ending the era of "no cure". For patients, this means a paradigm shift in fatty liver from "irreversible" to "reversible"—the initiative for liver health is returning to human hands.
🏆Asakusa Cosmetics provides you with
✔️ Authentic Smeglucopyranoside
✔️ Hospital prescription
✔️ Online doctor consultation
✔️ Pharmacist's Medication Instructions
✔️Comprehensive after-sales tracking service
⚠️ Friendly reminder: This article is for reference only. Please consult your doctor for specific medication advice.
-------------------------------------------------------------------------------------------------
📞Welcome to scroll down to contact customer service, purchase online, and have it shipped directly to your door.
🛒Click to learn more about purchasing details
🛒Semaglutide/Semaglutide Tablets 3mg 100 tablets (Japanese version)
🛒Semaglutide (Semaglutide) Tablets 7mg 100 tablets (Japanese version)
🛒Semaglutide/Semaglutide Tablets 14mg 100 Tablets (Japanese Version)